No products in the cart.

Anti-IGF1R antibody

SKU Product Brand Unit Availability Price Quantity  
AB-06-2358
Anti-IGF1R antibody
Erpan Tech In stock

Specifications        

Product Cat#: AB-06-2358
Product type: Primary antibody
Antigen: IGF1R
Immunogen: This antibody is produced by immunizing rabbits with recombinant protein of human IGF1R.
Species immunized: Rabbit
Isotype: IgG
Applications: Western Blot (1:500-1:2000); Immunohistochemistry (1:100-1:200)
Reactivity: Human
Clonality (clone number): Polyclonal
Form: Liquid
Buffer: 1*TBS (pH7.4), 0.5% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Concentration: 1 mg/ml
Purity: Protein A affinity purified
Storage: Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles.
Alternative names: CD221 antibody
CD221 antigen antibody
IGF 1 receptor antibody
IGF 1R antibody
IGF I receptor antibody
IGF-I receptor antibody
Igf1r antibody
IGF1R_HUMAN antibody
IGFIR antibody
IGFIRC antibody
IGFR antibody
Insulin like growth factor 1 receptor antibody
Insulin like growth factor 1 receptor precursor antibody
Insulin-like growth factor 1 receptor beta chain antibody
Insulin-like growth factor I receptor antibody
JTK13 antibody
MGC142170 antibody
MGC142172 antibody
MGC18216 antibody
Soluble IGF1R variant 1 antibody
Soluble IGF1R variant 2 antibody
Show More

Target information

Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.

Provider

Erpantech Laboratory

download

MSDS-AB-06-2358.pdf (105 downloads )